B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

HTR3A

MOLECULAR TARGET

5-hydroxytryptamine receptor 3A

UniProt: P46098NCBI Gene: 335918 compounds

HTR3A (5-hydroxytryptamine receptor 3A) is targeted by 18 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting HTR3A

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1Ondansetron3.8345
2Quipazine3.2625
3Metoclopramide3.0921
4Mianserin1.956
5Amitriptyline Tricyclic antidepressant with anticholinergic and sedative properties. It appears to prevent1.102
6Aripiprazole1.102
7Mescaline Hallucinogenic alkaloid isolated from1.102
8Octopamine1.102
9Pergolide1.102
10Sumatriptan1.102
11Amlodipine0.691
12Amoxapine0.691
13Astemizole Antihistamine drug now withdrawn from0.691
14Chlorhexidine0.691
15Cyproheptadine0.691
16Loxapine0.691
17Nortriptyline0.691
18Vortioxetine0.691

About HTR3A as a Drug Target

HTR3A (5-hydroxytryptamine receptor 3A) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 18 compounds with documented HTR3A interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

HTR3A inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.